Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes

被引:0
|
作者
Rosenzweig, Margaret Quinn [1 ]
Nugent, Bethany [2 ]
McGuire, Meaghan [2 ]
机构
[1] Univ Pittsburgh, Sch Nursing, Nursing, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
关键词
metastatic breast cancer; survival; race; neighborhood; health disparity; NEIGHBORHOOD DEPRIVATION; SURVIVAL; DISPARITIES; INDEX; RACISM; HEALTH;
D O I
10.1188/23.ONF.449-457
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVES: To describe area deprivation, anxiety, depression, relative dose intensity of first-line metastatic breast cancer (MBC) treatment, and survival in Black and White women who had died from triple-negative MBC, including interaction analysis. SAMPLE & SETTING: This cohort study drew from a database of women who had died from MBC (N = 53). METHODS & VARIABLES: Descriptive statistics, independent t tests, analysis of variance, and Mann-Whitney U tests were used, and effect sizes were calculated. RESULTS: Compared with White women, Black women reported higher anxiety and depression at MBC baseline. Black women living in areas of higher deprivation experienced shorter overall survival than White women living in similar areas (9.9 months versus 24.6 months). These results were not statistically significant, likely because of a small sample size, but were clinically meaningful. IMPLICATIONS FOR NURSING: Black and low-income women with breast cancer experience inferior survival as compared with White and higher-income women. Newer explanatory models for racial disparity in cancer outcomes include the assessment of neighborhood deprivation. White women may be less affected by their neighborhood, even when living in areas of greater deprivation influencing cancer outcomes. This merits further exploration.
引用
收藏
页码:449 / 457
页数:9
相关论文
共 50 条
  • [41] Metastatic triple-negative breast cancer: Established and emerging treatments
    Puri, Akshjot
    Reddy, Tejaswini P.
    Patel, Tejal A.
    Chang, Jenny C.
    BREAST JOURNAL, 2020, 26 (09): : 1793 - 1796
  • [42] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
    Arielle L. Heeke
    Antoinette R. Tan
    Cancer and Metastasis Reviews, 2021, 40 : 537 - 547
  • [43] Metastatic and triple-negative breast cancer: challenges and treatment options
    Al-Mahmood, Sumayah
    Sapiezynski, Justin
    Garbuzenko, Olga B.
    Minko, Tamara
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2018, 8 (05) : 1483 - 1507
  • [44] Emerging treatment strategies for metastatic triple-negative breast cancer
    Huppert, Laura A.
    Gumusay, Ozge
    Rugo, Hope S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [45] Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
    Saravia, Cesar H.
    Flores, Claudio
    Schwarz, Luis J.
    Bravo, Leny
    Zavaleta, Jenny
    Araujo, Jhajaira
    Neciosup, Silvia
    Pinto, Joseph A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [46] Innovations and Challenges in the Treatment of Metastatic Triple-Negative Breast Cancer
    McArthur, Heather L.
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (05) : 290 - +
  • [47] Treatment patterns in metastatic triple-negative breast cancer (mTNBC).
    Jiang, Shan
    Hill, Kala
    Della Varghese
    Waldeck, Adrian Reg
    Botteman, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Molecularly targeted therapies for metastatic triple-negative breast cancer
    Bayraktar, Soley
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (01) : 21 - 35
  • [49] Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer
    Hu, Xichun
    Xu, Binghe
    Cai, Li
    Wang, Zhonghua
    Wang, Biyun
    Zhang, Jian
    Teng, Yuee
    Tong, Zhongsheng
    Pan, Yueyin
    Yin, Yongmei
    Wu, Changping
    Jiang, Zefei
    Wang, Xiaojia
    Lou, Guyin
    Liu, Donggeng
    Feng, Jifeng
    Luo, Jianfeng
    Wu, Jiong
    Shao, Zhimin
    Ragaz, Joseph
    CANCER RESEARCH, 2015, 75
  • [50] How I treat metastatic triple-negative breast cancer
    Caparica, Rafael
    Lambertini, Matteo
    de Azambuja, Evandro
    ESMO OPEN, 2019, 4